TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from CureVac ( (CVAC) ).
On November 24, 2025, CureVac N.V. announced its financial results for the third quarter and first nine months of 2025. The company reported significant progress in its planned transaction with BioNTech, including obtaining clearance from the German Federal Cartel Office and the commencement of BioNTech’s public exchange offer for CureVac shares. CureVac’s financial performance showed a decrease in revenues compared to the previous year due to the absence of a one-time revenue from a prior agreement with GlaxoSmithKline. However, the company maintained a strong cash position and reaffirmed its cash runway into 2028. The announcement also highlighted ongoing developments in oncology, including the receipt of Clinical Trial Application clearance for a lung cancer therapy and progress in glioblastoma studies.
The most recent analyst rating on (CVAC) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s strong financial performance and attractive valuation are the primary drivers of its overall score. The company’s robust profitability metrics and low leverage enhance its financial stability. However, technical analysis indicates some short-term bearish momentum, which slightly offsets the positive financial and valuation aspects.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a pioneering multinational biotech company focused on developing transformative medicines based on messenger RNA (mRNA).
Average Trading Volume: 533,321
Technical Sentiment Signal: Hold
Current Market Cap: $1.13B
See more data about CVAC stock on TipRanks’ Stock Analysis page.